@tossydog I think it's worth adding to your summary the performance incentives for the BOD to complete ARDS, OSA and TBI trials completely as well as outline the Cannvalate Options Structure, Sud's CMO Package and the Med Board Incentive Package.
That combined with management's existing Top 10 Holdings (Paid For not freebies) and Sud/Cannvalate place as #1 holder puts REAL skin in the game for management. Extremely rare in spec end.
So far Incentive Structure for Med Board is
Then Sud's options at 20c
Then the remaining Cannvalate Options left in play.
These serve IMO as magnets for the SP, the BOD will want to reach these. The Cannvalate oppies expire 1st December this year and represent the deal where Cannvalate pays for the majority of costs associated with the trials. I feel like some punters dont REALIZE this and wonder how IHL will afford to run simultaneous clinical trials which cost millions. Well, we are capped at 80K GST per trial and Cannvalate pays the rest. These options are their reward. SP has to be >14c by December if not they just lost a lot of money.
Yet alone Sud's 20c which have to be trading at 20c or over for 5 trading days, and the 200M MC performance milestone... A lot to achieve, but I think it can be done by this year if the BOD pulls out all the stops.
IHL Price at posting:
7.0¢ Sentiment: Buy Disclosure: Held
